Osgood Schlatter Companies
Osgood-Schlatter disease is a medical condition that primarily affects adolescents, causing inflammation and pain below the knee joint where the patellar tendon attaches to the shinbone.
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Osgood-Schlatter Companies Update
Nov 2023: Due to its involvement in a "domestic antitrust cartel" in the United States, the American arm of the massive generic medication manufacturer Teva Pharmaceuticals faces a contract prohibition with the Canadian government that won't expire until the spring of 2025. In October, Teva Pharmaceuticals USA agreed to pay a US$225 million criminal penalty for participating in price-fixing conspiracies involving three pharmaceuticals in the United States. As a result, the company was placed on the Canadian government's list of suppliers ineligible or suspended. The company's local subsidiary, Teva Canada, is exempt from the prohibition, which is only set to expire in April 2025 but may be prolonged. According to a corporate regulatory attorney, it essentially amounts to a reprimand. According to the government's contract database, Teva Canada is currently involved in at least two active contracts. One is valued at more than $3 million and is for "multi-source pharmaceuticals," while the other was granted in July and is for generic medications valued at more than $700,000.
Sep 2023: Last year, the focus shifted from a large orthopedics acquisition to a business split that resulted in a spinoff, but now it is back on substantial dealmaking. Enovis, an independent medical technology company founded a year ago from the portfolio once owned by the Colfax group, has agreed to pay 800 million euros to purchase Lima, an Italian orthopedic implant maker. A cash payment of 700 million euros, or roughly $741 million in US dollars, is part of the deal; the remaining sum is paid in Enovis stock shares. The firms claim that the transaction will create a new billion-dollar participant in the reconstructive operations market, with around half of its revenue coming from the rapidly expanding body-extremity-focused industries. Early in 2024 is when the deal is expected to close.List of Osgood-Schlatter Key companies in the market
- DJO Global, Inc.
- Teva Pharmaceutical Industries Ltd.
- Breg, Inc.
- Bayer HealthCare Pharmaceuticals LLC
- Ossur HF
- Daiichi Sankyo Company, Limited
- Pfizer, Inc.
- Novartis AG
Osgood Schlatter Market Highlights:
Osgood Schlatter Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
